Tempus AI (TEM) is back in focus after announcing ALERT trial results showing its AI driven electronic health record alerts improved timely evaluations and valve interventions for patients with aortic stenosis and mitral regurgitation.
See our latest analysis for Tempus AI.
The ALERT trial news lands as the share price tells a mixed story, with a 3.5% 7 day share price return set against a 30 day share price return of 10.4% and a 90 day share price return of 32.9%. The 1 year total shareholder return of 25.8% shows longer term holders have had a different experience to recent buyers.
If this kind of healthcare AI progress has your attention, it could be a good moment to see what else is emerging across 37 healthcare AI stocks
ALERT’s cardiology results, rising revenues of US$1,271.8m and an annual net loss of US$245.0m now sit against a share price that is 39% below analyst targets. This raises the question: is there genuine upside here, or is future growth already baked in?
Most Popular Narrative: 39.9% Undervalued
Tempus AI's most followed narrative pegs fair value at $77.93 per share versus the last close of $46.82, putting a spotlight on what is driving that gap.
Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage.
Curious what kind of revenue trajectory and margin shift would need to unfold for that price to make sense? The narrative leans heavily on faster top line growth, a swing from losses toward healthy profitability, and a richer future earnings multiple that assumes Tempus AI can convert its data assets into cash flow at scale.
Result: Fair Value of $77.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh risks such as tougher genomics competition and uncertain reimbursement for new assays, which could pressure margins and delay the path to profitability.
Find out about the key risks to this Tempus AI narrative.
Another View: What The P/S Multiple Is Signalling
That 39.9% “undervalued” fair value sits alongside a very different signal from the market. Tempus AI trades on a P/S of 6.6x, compared with 2.9x for the US Life Sciences industry and 3.5x for peers, while the fair ratio sits near 6.7x.
In simple terms, the share price already carries a much richer revenue multiple than the broader group, with only a small gap to the fair ratio. Is that a margin of safety, or are you paying up for a story that still has to turn losses into profits over time?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals across valuation, growth expectations and profitability, this is the moment to move fast, review the underlying data and pressure test the story for yourself. Start with the 2 key rewards and 2 important warning signs.
Ready for more investment ideas?
If Tempus AI is on your radar, do not stop there. A few minutes with high quality screeners could surface opportunities you will wish you had seen earlier.
- Target potential upside by scanning companies that appear mispriced relative to fundamentals using the 61 high quality undervalued stocks.
- Prioritize resilience by focusing on businesses highlighted in the 70 resilient stocks with low risk scores that score well on financial strength and risk checks.
- Spot earlier stage opportunities with solid underpinnings through the screener containing 25 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com